Holen Sie sich die Stockscreener-App
4.83
3.01%
-0.15
Handel nachbörslich:
4.88
0.05
+1.04%
Schlusskurs vom Vortag:
$4.98
Offen:
$4.96
24-Stunden-Volumen:
50,167
Relative Volume:
0.18
Marktkapitalisierung:
$34.83M
Einnahmen:
$151.93M
Nettoeinkommen (Verlust:
$23.40M
KGV:
2.2033
EPS:
2.1922
Netto-Cashflow:
$-69.80M
1W Leistung:
-4.17%
1M Leistung:
-64.67%
6M Leistung:
-55.91%
1J Leistung:
-47.84%
1-Tages-Spanne:
$4.80
$5.11
1-Wochen-Bereich:
$4.50
$5.18
52-Wochen-Spanne:
$4.20
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
4.83 | 35.91M | 151.93M | 23.40M | -69.80M | 2.1922 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.48 | 119.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.91 | 82.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.16 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.98 | 42.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.43 | 38.60B | 4.98B | 69.60M | 525.67M | 0.5198 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
Nasdaq Moves: Will Atara Biotherapeutics Inc benefit from green energy policiesLayoff News & Community Supported Trade Ideas - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - Chartmill
Highs Report: What analysts say about Atara Biotherapeutics Inc stockMarket Weekly Review & AI Forecast Swing Trade Picks - baoquankhu1.vn
Fundamentals Check: Does Nuveen Churchill Direct Lending Corp have pricing powerJuly 2025 WrapUp & Weekly High Momentum Picks - baoquankhu1.vn
Can Atara Biotherapeutics Inc stock double in the next yearMarket Activity Report & Accurate Intraday Trade Tips - baoquankhu1.vn
Is Atara Biotherapeutics Inc. stock influenced by commodity pricesJuly 2025 Recap & Reliable Breakout Stock Forecasts - mfd.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - Chartmill
Once a Ventura County biotech heavyweight, Atara fights for its life - Ventura County Star
Price-Driven Insight from (ATRA) for Rule-Based Strategy - Stock Traders Daily
Short Squeeze: Can Atara Biotherapeutics Inc weather a recessionJuly 2025 WrapUp & Low Drawdown Trading Techniques - baoquankhu1.vn
Patterns Watch: Can Atara Biotherapeutics Inc weather a recessionMarket Sentiment Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Pancreatic Cancer Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart.com
Tabelecleucel’s Phase 3 EBV+ PTLD Trial Progress Signals Continued Potential for Atara Biotherapeutics - TipRanks
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - FinancialContent
What momentum indicators show for Atara Biotherapeutics Inc. stockMarket Rumors and News & Trusted Financial Advisors at No Cost - bollywoodhelpline.com
FDA Again Rejects Atara - labusinessjournal.com
Analyst Calls: Can Ligand Pharmaceuticals Incorporated beat the S P 5002025 Price Momentum & Trade Opportunity Analysis - baoquankhu1.vn
Aug Summary: Will HAFN benefit from green energy policiesStock Surge & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Innovation Ltd Panacea Sells 80,554 Shares of Atara Biotherapeutics (NASDAQ:ATRA) Stock - Defense World
(ATRA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Atara Bio director Huang James sells $489k in shares By Investing.com - Investing.com India
Atara Bio director Huang James sells $489k in shares - Investing.com
Aug Selloffs: Is Atara Biotherapeutics Inc being accumulated by smart moneyTrade Exit Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
FDA Reversal Sends Atara Biotherapeutics into Tailspin: Stock Plummets 67% on Second CRL for Tabelecleucel - FinancialContent
Entry Recap: Is Atara Biotherapeutics Inc stock dividend yield sustainableJuly 2025 Retail & Daily Profit Maximizing Tips - Bộ Nội Vụ
Canaccord Genuity Downgrades Atara Biotherapeutics (ATRA) to Hol - GuruFocus
Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier) - TipRanks
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Atara receives FDA complete response letter for Ebvallo BLA application - Pharmaceutical Business review -
FDA rejects Atara’s tabelecleucel application in surprise reversal By Investing.com - Investing.com Nigeria
Canaccord Genuity Downgrades Atara Biotherapeutics to Hold From Buy, Adjusts PT to $6 From $25 - marketscreener.com
Atara Biotherapeutics' EBVALLO BLA Rejected by FDA, Stock Plummets 57% - Intellectia AI
Atara Biotherapeutics Stock Falls After FDA CRL On EBVALLO BLA - RTTNews
ATRA stock nearly halves in value after FDA refuses approval for immunotherapy: Retail sees 'big fight back' - MSN
FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain - TipRanks
FDA rejects Atara’s tabelecleucel application in surprise reversal - Investing.com
Atara Biotherapeutics (ATRA) Shares Plunge After FDA Setback - GuruFocus
Atara plummets on FDA Complete Response Letter for tabelecleucel - Seeking Alpha
ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’ - Stocktwits
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
FDA Hits Atara Biotherapeutics’ T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD With Second CRL - CGTLive®
Atara, Pierre Fabre allege FDA about-face as agency hands down 2nd Ebvallo snub - Fierce Pharma
Why Is Atara Biotherapeutics Stock Sinking Monday?Atara Biotherapeutics (NASDAQ:ATRA) - Benzinga
US FDA declines to approve Atara's therapy for rare blood cancer - Reuters
Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next - TechStock²
FDA Rejects Atara's (ATRA) Ebvallo BLA: Calls for New Evidence o - GuruFocus
US FDA declines to approve Atara’s therapy for rare blood cancer - PharmaLive
Atara's cell therapy is again rejected by FDA, cites agency reversing position on single-arm study - Endpoints News
Atara Biotherapeutics stock plunges after FDA rejects cancer therapy By Investing.com - Investing.com Canada
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
1.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):